Stepping into a New Era – Sotatercept for the Treatment of Cpc-PH from HFpEF

Key Points

• The aim is to evaluate the efficacy of sotatercept in treating chronic precapillary pulmonary hypertension (cpc-ph) resulting from heart failure with preserved ejection fraction (hfpef).
• Conducted a randomized trial with cpc-ph patients associated with hfpef.
• Administered sotatercept and assessed pulmonary pressures.
• Analyzed treatment effects on symptoms and quality of life.
• Sotatercept significantly reduced mean pulmonary artery pressure (p < 0.001).
• Patients experienced improved exercise capacity with a 35% increase in 6-minute walk distance (95% CI, 20-50).
• Quality of life scores improved, indicating enhanced functional status.